ESTRO 2021 Abstract Book

S1180

ESTRO 2021

analyse individual patient data for better understanding of paediatric cancer patterns in India. The question of whether the present study truly depicts the regional prevalence can only be resolved by creation of a central database from all parts of India. However, our study adds significant information to the available epidemiological aspects of paediatric tumors in India. PO-1437 Endocrine Late- Effects after Childhood and Adolescent Cancer - The Pan-European Registry HARMONIC M.R. Wette 1 , T. Steinmeier 1 , Y. Lin 1 , N. Journy 2 , T. Tran 2 , A. Jackson 2 , S. Bolle 3 , B. Fresneau 3 , Y. Lassen- Ramshad 4 , L. Tram Henriksen 5,6 , K. Haustermans 7 , L. Brualla 8 , C. Bäumer 1 , C. Demoor-Goldschmidt 2,9 , J. Thariat 10 , I. Thierry-Chef 11,12,13 , B. Timmermann 8,14 1 Department of Particle Therapy- University Hospital Essen, West German Proton Therapy Centre Essen WPE, West German Cancer Centre WTZ- Germany, Essen, Germany; 2 French National Institute of Health and Medical Research, Inserm, Paris, France; 3 Gustave Roussy- Paris-Saclay University, Department of Radiation Oncology, Villejuif, France; 4 Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; 5 Pediatric Department, Aarhus University Hospital (AUH), Aarhus, Denmark; 6 Aarhus University, (AU), Aarhus, Denmark; 7 KU Leuven - University of Leuven, Department of Radiation Oncology- University Hospitals Leuven, Leuven, Belgium; 8 Department of Particle Therapy- University Hospital Essen, West German Proton Therapy Centre Essen WPE, West German Cancer Centre WTZ- Germany , Essen, Germany; 9 Centre Régional François Baclesse CRFB, Department of Radiation Oncology, Caen, France; 10 Centre Régional François Baclesse CRFB, Department of Radiation Oncology , Caen, France; 11 Institute for Global Health of Barcelona, ISGlobal, Barcelona, Spain; 12 Universitat Pompeu Fabra , (UPF), Barcelona, Spain; 13 Ciber Epidemiología y Salud Pública , CIBERESP, Madrid, Spain; 14 German Cancer Consortium , (DKTK), Essen/Düsseldorf, Germany Purpose or Objective After irradiating central nervous system (CNS) or head and neck sites, the risk for endocrine dysfunction is well known. Nevertheless, the impact of modern radiotherapy (RT) techniques on endocrine glands needs further investigations, standardised data collection and international collaboration. The EU-funded HARMONIC project is currently setting up a pan-European registry of paediatric patients treated with modern RT techniques. The registry comprises, among other things, database structure and eCRFs (electronic clinical record files) on endocrine structures. Objectives of this project are to investigate the possible predictors and correlations between radiation exposure and long-term impact on endocrine function, taking into account the different therapy modalities, and to establish valid recommendations for treatment guidelines as a part of individualised patient care. Materials and Methods Research Electronic Data Capture was chosen as the platform for retrospective (since 2000) and prospective clinical data, enabling data matching with US registries. eCRFs were particularly designed for the endocrine assessment including optional and mandatory parameters, such as puberty development according to Tanner, growth data (in sitting, hip and abdominal girth) as well as thyroid, growth and sex hormones were considered. Furthermore, RT-related data in terms of dose-volume constraints were also considered. Clinical examinations are conducted at baseline and up to 120 months after RT. A procedure on contouring endocrine organs, i.e. hypothalamus, pituitary gland and thyroid, and their respective substructures was defined. Additionally, a standardised workflow for data collection was implemented. Pretesting of database (about 6 months), contouring standard and workflow tests were carried out based on defined qualitative validation criteria for feasibility in routine clinical practice. Results The HARMONIC database contains about 400 parameters, including 22 for endocrine assessment. After pretesting the database, 11 parameters were modified according to the qualitative criteria (time of collection, extra effort) and consequently the workflow was adapted. When contouring the substructures of hypothalamus and pituitary gland, the need for more practice was identified due to size of structure, patient’s individual structure conditions and previous operations. A training concept to contour the new structures will prospectively be introduced. Conclusion The HARMONIC framework will enable the assessment of late endocrine outcomes of childhood and adolescent cancers treated with modern RT techniques. Hence, the database will allow quantification of dose-volume effects on endocrine structures and will provide the radiation and paediatric oncology communities with research strategies, methods and infrastructures due to treatment decisions. Thus, it will contribute to improve patient care and quality of life of affected patients. PO-1438 Treatment outcome and prognostic factors in paediatric ependymoma M. Bishr 1 , F. Carceller 2 , F. Saran 3 , S. Vaidya 2 , K. Powell 2 , J. Stone 2 , C. Chandler 4 , B. Zebian 4 , S. Stapleton 5 , S. Hettige 5 , L. Marshall 2 , H. Mandeville 2 1 University College London Hospitals NHS Foundation Trust, Department of Oncology, London, United Kingdom; 2 Royal Marsden NHS Foundation Trust, Children and Young People’s Unit, Sutton, United Kingdom; 3 Auckland City Hospital, Department of Radiotherapy, Auckland, New Zealand; 4 King’s College Hospital NHS Foundation Trust, Department of Neurosurgery, London, United Kingdom; 5 St George's University Hospitals NHS Foundation Trust, Department of Neurosurgery, London, United Kingdom Purpose or Objective Ependymoma is the third most common primary brain tumour in children and adolescents, and most cases are diagnosed before the age of 5 years. The present study reports the treatment outcome and prognostic factors in children and young adults with ependymoma treated at a single institute. Materials and Methods Paediatric and young adult patients (≤ 25 years old) with a histological diagnosis of ependymoma between